Abstract
Bioassay-guided fractionation of Papua New Guinea collections of Leucosolenia sp. resulted in the isolation of the novel compounds leucosolenamines A (5) and B (6) and the known compound thymidine (7). Compound 5 contains a 2-aminoimidazole core substituted at C-4 and C-5 by an N,N-dimethyl-5,6-diaminopyrimidine-2,4-dione and a benzyl group, respectively. Compound 6 retains the same core structure; however C-4 is substituted by a 5,6-diamino-1,3-dimethyl-4-(methylimino)-3,4-dihydropyrimidin-2(1H)-one moiety. This substitution pattern is unique and has never been observed in calcareous imidazole alkaloid chemistry. Leucosolenamine A (5) was mildly cytotoxic against the murine colon adenocarcinoma C-38 cell line.
The sustained position of marine sponges as a source of structurally diverse and biologically active natural products was emphasized in a recent review article covering the 2003 literature.1 Complex sponge natural products have also been the basis for the development of several clinical leads.2 At the top of the list are natural products containing multiple chiral centers such as the bengamides,3 fijianolides,4 the halichondrin analogue E7389,5 and the discodermolides6 or sponge metabolites with exotic functionality, as in the psammaplins.7 The research described in this paper began with the goal of adding additional unique structures to the rapidly growing list of sponge-derived alkaloids. In this regard, the Calcarea class of sponges is now recognized as a reliable source of richly bioactive metabolites possessing a 2-aminoimidazole8 core that is often further substituted at the C-4 and C-5 positions.9 The range of substitution patterns observed to date at these positions include (a) benzyl side chains, (b) oxo groups at C-4, and (c) annulation by five- or six-membered rings. The structures of naamine C (1),10 leucettamine B (2),11 spirocalcaridine A (3),8c and 2-amino-2-deoxykealiiquinone (4)12 provide illustrations of these structural features.
Investigations to date of Calcarea sponges have been restricted to the genera Leucetta (syn. Pericharax) and Clathrina (both of the order Clathrinida, family Leucettidae). Yet, in view of the rich chemistry discovered, it is surprising that very little chemical work has been conducted on other members of this taxonomic class comprised of sponges in five orders spanning more than 75 genera.13 The major impediment to further studies of this group is that they appear to be less abundant and poorly described in comparison to the class Demospongiae. During recent expeditions to Papua New Guinea (PNG), specimens of the genus Leucosolenia (order Leucosolenida, family Lecucosoleniidae) were obtained and became high priority for further investigation because the crude MeOH extract showed positive activity in our primary screen for in vitro solid tumor selectivity.14 Disclosed below are the results of this study culminating in the characterization two new compounds, leucosolenamines A (5) and B (6), possessing a 2-amino imidazole core substituted at C-4 and C-5, and the isolation of thymidine (7).
Results and Discussion
The PNG sponge Leucosolenia sp. (coll. no. 03528) yielded three extracts using an accelerated solvent extraction process. The methanol-soluble fraction, coded XFM, had selective bioactivity (for murine adenocarcinoma C-38 cell line) in the disk diffusion solid tumor whole cell assay with an inhibitory zone differential of 9 mm between murine C-38 and CFU-GM cells at 180 µg per disk.14 Because of this selective bioactivity, the MeOH fraction was subjected to HPLC purification to afford five fractions (Figure S2). Fraction 3 was pure leucosolenamine A (5) (5.6 mg) with an m/z of 384.2 [M + H]+ (ESI-TOF) and exhibited inhibition zones of 10.5 mm (at 180 µg per disk) against murine colon 38 (vs 0 mm against CFU-GM). Fraction 1 (coded XFMP1) was also active and showed an inhibition zone of 21 mm (at 180 µg per disk) against C-38 and was further purified by HPLC to yield thymidine (7) (12.2 mg). Additional samples of Leucosolenia sp. (coll. no. 05413 and 06231) were also examined to isolate more of 5. To our delight, these two collections (vide infra) yielded 5 accompanied by a new analogue, leucosolenamine B (6).
The structure elucidation of 5 began by dereplicating against known sponge-derived metabolites, and the only literature match, naamine C (1)10 [C21H25N3O4, 383 amu], was confidently ruled out from the atom count assessed by NMR. A partial formula for 5 of C17H13O2N3 was supported by (a) the 13C and DEPT NMR data (Table 1) showing 10 quaternary, three methine, two methylene, and two methyl carbons, (b) the äC 160.1 characteristic of a guanidine residue of a 2-amino imidazole group, and (c) the äC/äH 100.5/5.90 (s, 2H’s) indicative of the 1,3 dioxolane ring as seen in leucettamine B (2).11
Table 1.
| 5 (in DMSO-d6) |
2 (in Me2CO-d6) |
||||
|---|---|---|---|---|---|
| C# | δ C | δH mult. J (Hz), int. | gHMBC | δ C | δH mult. J (Hz), int. |
| 2 | 160.1 | 160.2 | |||
| 4 | 148.0 | 170.5 | |||
| 5 | 158.0 | 140.4 | |||
| 6 | 38.1 | 4.05 s, 2H | C-4, C-5, C-7, C-8, C-12 | 114.6 | 6.42 s, 1H |
| 7 | 133.2 | 131.7 | |||
| 8 | 109.7 | 6.97 d, J 1.5, 1H | C-6, C-9, C-10, C-12 | 110.8 | 8.04 d, J 1.6, 1H |
| 9 | 146.8 | 148.6 | |||
| 10 | 145.3 | 148.1 | |||
| 11 | 107.8 | 6.73 d, J 8.0, 1H | C-9, C-7 | 108.8 | 6.82 d, J 8.1, 1H |
| 12 | 121.9 | 6.79 dd, J 1.5, 8.0, 1H | C-6, C-8, C-10 | 126.3 | 7.33 dd, J 1.6, 8.1, 1H |
| 13 | 100.5 | 5.90 s, 2H | C-9, C-10 | 102.0 | 6.01 s, 2H |
| 2′ | 150.8 | ||||
| 4′ | 146.3 | ||||
| 5′ | 113.7 | ||||
| 6′ | 159.5 | ||||
| CH3-N-1′ | 28.0 | 3.24 s, 3H | C-2′, C-6′ | ||
| CH3-N-3′ | 28.8 | 3.39 s, 3H | C-2′, C-4′ | ||
Measured at 500 MHz (1H) and 125 MHz (13C).
Ref 11.
Successive sets of high-resolution mass spectrometry data were needed to finalize the molecular formula of 5 as C17H17O4N7. The HRESI-TOFMS gave an [M + H]+ m/z of 384.1776; however, more accurate data were obtained later by the FTICRMS15 [M + H]+ m/z of 384.14161. Initially we considered three formulas based on the ESI-TOF peak as follows: (i) C17H22O2N9 (¢12 mmu vs calc), (ii) C17H18O4N7 (¢36 mmu vs calc), and (iii) C17H18O4N7 (¢83 mmu vs calc). At this point in the analysis (i) was favored; however, the ultrahigh-resolution data indicated the best match was with (ii) because of the following pattern of ¢ mmu vs calc: (ii) = 0.04, (iii) = 47.2, and (i) = 48.0. Comparing the final formula to the partial formula derived by NMR as noted above indicated that four heteroatom-attached hydrogens were present and an unsaturation number of 13 was required.
The 1H NMR spectrum of 5 (Figure S4) was not information rich, as it showed just seven types of signals. As a confounding complication, none of the four heteroatom protons were visible by 1H NMR using a variety of solvents. There was an ABX spin system for a 1,2,4-trisubstituted benzene ring identified by a double doublet at δ 6.79 (J = 1.5, 8.0 Hz), a doublet at ä 6.97 (J = 1.5 Hz), and a doublet at δ 6.73 (J = 8.0 Hz). This diagnostic spin system, the methylene singlet at δ 4.05, and the additional methylene singlet (δ 5.90) noted above justified substructure A (Figure 1). This array was confirmed by gHMBC correlations illustrated in Figure 1 and further justified by comparison of NMR properties of A to the parallel peaks of leucettamine B (2).11 The remaining observed protons were identified as N-methyl singlets at δ 3.39 and 3.24 that flanked the intense water peak.
Figure 1.

Substructures with observed gHMBC correlations of 5.
The process of accounting for the seven nitrogens and four hetero-attached protons of 5 began with the linking of substructure A to a 2N-imidazole ring, resulting in substructure B. This proposal was initially envisioned in order to account for the extraordinarily low field shift of the aliphatic benzylic hydrogens (δ 4.05). The gHMBC correlations shown in Figure 1 were in full agreement with attachment of this heterocyclic ring to C-6. A side-by-side comparison of the 13C and 1H NMR data of leucosolenamine (5) and leucettamine B (2) at atom numbers 2 and 7-13 provided expected similarities, as shown in Table 1, which further documented their congruent structural features. The obvious differences between these two compounds were also reflected in differing shifts at atom numbers 4-6.
The extremely difficult final task involved assembling one or more substructures to explain the remaining unaccounted atoms of C6H10O2N4. The 13C NMR signals to be rationalized consisted of four quaternary carbons (δC 159.5, 150.8, 146.3, and 113.7). Also needing a specific assignment were the two N-methyls (δC/H 28.8/3.39 and 28.8/3.24), noted above. A 5,6-dinitrogen-substituted uracil with N-methylation at both ring nitrogens, as shown in substructure C of Figure 1, was envisioned and was consistent with these data. Validation of this proposal was partially provided by gHMBC correlations, outlined in Figure 1, from HCH3-N-1′ (δH 3.24) to C-2′ (δC 150.8) and to C-6′ (δC 159.5) and from HCH3-N-3′ (φH 3.39) to C-2′ (δC 150.8) and to C-4′ (δC 146.3).
The process of merging structures B and C was not straightforward because, as noted above, all attempts to visualize the four NH 1H NMR resonances were unsuccessful. To summarize the constraints established above, there were three bridging atom sites in B and two in C, resulting in a total of six possible working structures, shown in Figure 2. These structures could be divided into two sets on the basis of the presence of an NH2 group at C-5′ or at C-4′, consisting of I-III and IV-VI, respectively. Two structures, I and IV, of Figure 2, follow the substitution pattern seen in the naamidines16 and pyronaamidines,17 as they retain the commonly observed 2-aminoimidazole ring. However one significant change includes a pyrimidinedione moiety attached to the exocyclic nitrogen and the N-substitution at C-4 is without biosynthetic precedent. The same unprecedented situation, N-substitution at C-4, holds for all other structures (II, III, V, and VI). Attempts to distinguish among these six possibilities aided by NOE data were unsuccessful, as no correlations were observed between the N-Me groups of substructure C and the sp3 and sp2 protons of substructure B. The only NOE correlations observed were from H-6 (′H δH 4.05) to H-8 (δH 6.97) and H-12 (δH 6.79) and vice versa.
Figure 2.
Evaluation of the six possible working structures of leucosolenamine (5) via 13C chemical shifts. The carbon numbers are listed above each bar. R = benzo-1,3-dioxole moiety.
We next turned to analyzing the 13C chemical shifts expected for these possibilities and focused on three observed signals, at δ 113, 146, and 148, that appeared to be distinctive. The calculated 13C chemical shifts (ACD software) versus experimental data are shown in Figure 2 (and Figure S9), and agreement of these data within (5 ppm was considered to be diagnostic. The three key observations were as follows: (a) only structures I, II, and III showed good agreement for the data at C-5[.minute], (b) the data set at C-4/C-4′ showed agreement for structures I and II, and not III or V, and (c) the data set at C-5 and C-2 showed the best agreement for structure I. Thus I emerged as the most consistent candidate, as shown by the excellent agreement of the δC-calc to δC-obsv and was confidently concluded to be the final structure of 5 (Figure 2). As seen here, employing database software to calculate 13C shifts is becoming an invaluable tool to confirm structural assignments.18
To further substantiate the above conclusion, 5 was subjected to MS-MS in both positive and negative ion modes. The negative ion experiment gave an m/z 382.17 [M - H]-, and further MS-MS on this ion produced a single fragment at m/z 340.01 corresponding to a loss of CN2H2, as shown in Figure 3. MS-MS on m/z of 340.01 resulted in a fragment ion of m/z 312.17 from a loss of CO. The direct loss of CN2H2 was not compatible with structure III or VI due to differences in regiochemistry, leaving two remaining possible mechanisms to explain these results. We preferred fragmentation pathway A beginning with I or IV involving two C-N bond cleavages at N-1-C-2 and N-3-C-4. As explained below, pathway B was less favored and resulted from a C-N bond cleavage occurring from II or V at the C-4-C-5 and C-2-N-3 bonds. Additional observations supporting pathway A were obtained by MS-MS on N,N-dimethylnaamidine D (8, Figure S15) and leucettamine B (2, Figure S16). The MS-MS on the [M + H]+ at m/z 352.33 for 8 resulted in a loss of an anisole moiety to give fragment m/z 244.14, and further MS-MS on this fragment afforded the peak at m/z 188.04 rationalized by a loss of C2N2H4 and is consistent with a N-1-C-2 and N-3-C-4 cleavage, shown in Figure 3A. A similar cleavage process was observed when a leucettamine B (2) [M - H]- peak at m/z 244.09 was subjected to MS-MS, eventually affording the peak at m/z 159.00 from loss of C2N2H3 also via N-1-C-2 and N-3-C-4 cleavage, shown in Figure 3A. The key observation here is that the MS-MS data of 2 and 8 failed to show the cleavage at the C-4-C-5 bond expected via pathway B (as illustrated in Figure S16B). Some additional observations from the MS-MS data were not diagnostic as follows. Additional MS-MS on m/z 340.01 for 5 gave a new ion at m/z 312.17 from loss of CO to structure 5ii. Positive ion mode MS-MS analysis of 5 (Figure S17) also gave interesting results but similar to the preceding data did not differentiate between structures I, II, IV, and V.
Figure 3.
Proposed MS-MS fragmentation pattern of 5. Pathway A rationalizes the fragmentation patterns for structures I and IV, while pathway B details the fragmentation patterns for II and V. See Figure 2 for candidate structures I, II, IV, and V. CE = collision energies set at 30 eV.

An especially critical step in evaluating the structure of 5 pertained to focusing on the major tautomer between the two possibilities shown in Figure 4. The NMR data of 5 clearly showed that only one major tautomer (structure I of Figure 2) was present, and this was concluded to be 5a on the basis of the results of relative energies from MOPAC calculations and the best fit between observed and experimental 13C shifts (Figure S18). Interestingly, the fully minimized structure of both tautomers (Figure S19) predicted that the phenyl ring and the pyrimidine ring should be positioned away from each other as shown and is consistent with the lack of NOE correlations between the proton-containing residues of these two rings.
Figure 4.
Relative energies of the two tautomeric forms of 5
We sought to extend the results obtained above by examining two additional PNG collections of this species. The two collections (nos. 05413 and 06123) were selected, and their crude extracts were combined and processed as described for collection no. 03528 (Figure S2). From the crude methanol extract six preparative HPLC fractions were obtained. Fraction 4 contained 5 (5.6 mg) and fraction 3 was further purified to give leucosolenamine B (6) (1.3 mg).
The structure elucidation of 6 began with obtaining a molecular formula from the HRESITOFMS [M + H]+ m/z 397.1658, indicating C18H21N8O3 (Δ 7.0 mmu vs calc) and required 13 degrees of unsaturation. Comparing this formula to that of 5 showed a difference of +C1H3N and -O, making it evident that one of the CdO in 5 was replaced by a CdNCH3 group in 6. Using the new NMR data in Table 2 for a side-by-side comparison with that of Table 1 indicated many structural similarities between the two compounds. The only differences in their 13C NMR are an upfield shift of δC-6[.minute] in 6 at 145.3 versus δC-6′ 159.5 in 5 plus there was an extra methyl signal at ′ 38.1. From these NMR comparisons it was clear that 6 also contains a dioxybenzo-2-aminoimidazole and a 5,6-dinitrogen-substituted uracil moiety. These were confirmed by gHMBC correlations as illustrated in Figure 1, substructure B, and in Figure 5, substructure D. The important gHMBC correlations to fix the position of the CdNCH3 are shown and were as follows. One set involved the correlation from methyl protons δ 3.55 and 3.22 to δC-6[.minute] 145.3, and the other set involved correlations from methyl protons δ 3.17 and 3.22 to δC-2[.minute] 150.8. The chemical shift of C-6[.minute] is consistent with that observed in synthetic purinone derivatives with their N-methylimino carbons resonating at ~δC 144-147 (Figure S26).19
Table 2.
NMR Data of Leucosolenamine B (6) in DMSO-d6 at 500 MHz (1H) and 125 MHz (13C)
| C# | δ C | δH mult. J (Hz), int. | gHMBC |
|---|---|---|---|
| 2 | 159.7 | ||
| 4 | 144.3 | ||
| 5 | 155.5 | ||
| 6 | 38.2 | 4.01, s, 2H | 4, 5, 7, 8, 12 |
| 7 | 133.6 | ||
| 8 | 110.0 | 6.93, d, 2.5, 1H | 9, 10, 12 |
| 9 | 146.8 | ||
| 10 | 145.3 | ||
| 11 | 107.9 | 6.75, d, 8.0, 1H | 7, 9, 10, 12 |
| 12 | 122.1 | 6.80, dd, 8.0, 2.5, 1H | 6, 7, 8, 11 |
| 13 | 100.6 | 5.91, s, 2H | 9, 10 |
| 2′ | 150.8 | ||
| 4′ | 143.8 | ||
| 5′ | 115.4 | ||
| 6′ | 145.3 | ||
| CH3-N1′ | 29.9 | 3.22, s, 3H | 2′, 6′ |
| CH3-N3′ | 28.7 | 3.17, s, 3H | 2′, 4′ |
| CH3-N6′ | 38.1 | 3.55, s, 3H | 6′ |
Figure 5.

Substructure D showing 13C chemical shifts and gHMBC correlations.
Substructures B and D were then combined on the basis of parallel 13C chemical shifts and biogenetic comparison to 5 to give the final structure of 6. The analysis according to the strategy of Figure 4 (Figure S18) supported the tautomer shown. Last, a ROESY experiment on 6 showed only correlations from H-6 (′H 4.01) to H-8 (′H 6.39) and H-12 (δH 6.80), while no correlations were observed between the three N-Me protons of substructure D or from these protons to those of substructure B. From these observations, it was concluded that CH3-N6[.minute] is trans to CH3-N1′, as shown in the final structure of 6, and that the phenyl ring and the pyrimidine ring should be positioned away from each other as discussed above for 5.
Our investigation of the biological properties was restricted to an evaluation of 5 due to sample limitation and stability. The data set summarized in Table 3 employed our standard disk diffusion assay14 and revealed that 5, at 180 μg/disk, inhibited murine C-38 cells with a 10.5 mm zone as compared to 0 mm against CFU-GM cells. This is the profile for a mildly potent selective cytotoxin when compared to the in vivo active agent bengamide E,20displaying at 7.8 μg/disk inhibition zones of 21 mm against C-38 and 16.5 mm against CFU-GM cells. A similar pattern was observed for a semipure fraction (coded XFMP1) that yielded thymidine (7), and it showed a zone of inhibition of 21 mm against C-38 cells versus 4.5 mm against CFU-GM at 180 μg/disk. However, pure 7 was inactive when reassayed against C-38 and CFU-GM cells. Unfortunately, it has not been possible to date to isolate the active component of this semipure fraction.
Table 3.
Zone Unit Differentials in the Disk Diffusion Soft Agar Colony-Forming Assaya
| compound | conc, μg/disk | ZC–38 – ZCFU –gm/mm |
|---|---|---|
| bengamide E (standard) | 7.8 | 4.5 |
| crude MeOH extract | 180 | 9 |
| 5 | 180 | 10.5 |
| XFMP1 | 180 | 16.5 |
| 7 | 180 | 0 |
Murine cell lines: C-38, colon adenocarcinoma; CFU-GM, colony-forming unit-granulocyte macrophage; normal hematopoietic. Significant selectivity is defined by a difference of ≥7.5 mm zone unit differentials. XFMP1 is semipure and contains thymidine.
The overall structures of leucosolenamines A (5) and B (6) while not overly complex are unprecedented and presented an extreme challenge to characterize. Their core structure retains the 2-amino imidazole array observed in other calcareous sponges. The substitution of N,N-dimethyl-5,6-diaminopyrimidine-2,4-dione and 5,6-di-amino-1,3-dimethyl-4-(methylimino)-3,4-dihydropyrimidin-2(1H)-one at C-4 is unique and represents a new structural theme in calcareous imidazole alkaloid chemistry. Substructure C has been observed as a natural product in 1,3-dimethyl-4,5-diamino-2,6-dihydroxypyrimidine from an Aspergillus nidulans21 and in hymeniacidin from a marine Hymeniacidon sponge.22 Of additional note, this substructure is embedded in the pteridine ring of leucettidine (9), isolated from a Bermuda collection of Leucetta microraphis.23 The discovery of 5 and 6 from Leucosolenia represents the first natural products from this genus and provides a stimulus to explore the other unstudied orders of the class Calcarea.

Experimental Section
General Experimental Procedures
NMR spectra were obtained using a Varian Unity 500+ at 500 MHz for 1H and 125 MHz for 13C employing internal standards: DMSO-d6 at δH 2.50 and δC 39.57. Multiplicities of 13C NMR peaks were determined using DEPT and gHMQC data. 13C NMR data of 6 were measured using a direct detection 13C nano probe. Low- and high-resolution mass spectrometry was performed on a benchtop Mariner electrospray ionization time-of-flight instrument (ESITOF). Ultrahigh-resolution mass measurements were obtained via positive mode on a Finnigan FTICR hybrid mass spectrometer, which combines ion trap and Fourier transform ion cyclotron resonance.15 MS-MS measurements were done using a LTQ mass spectrometer. Preparative HPLC was carried out using a single-wavelength (λ = 254 nm) UV detector and evaporative light-scattering detector (ELSD) in series with a Waters RP C18, 5 μm particle column. Computer modeling and calculations were done using ACD/13C NMR DB version 8.00 (May 4th, 2005).
Biological Material
The sponge samples (UCSC coll. nos. 03528, 05413, 06123) were collected by scuba from a variety of sites off Milne Bay in Papua New Guinea at depths of 30—70 ft. The sponge was identified by Prof. Rob van Soest as a Leucosolenia sp., and a voucher sample has been deposited at the Zoological Museum of Amsterdam (ZMAPOR 17556). Voucher specimens and underwater photos are available from the author (P.C.).
Isolation
The sponge samples were preserved in the field according to our standard procedure and transported back to the laboratory at ambient temperature.24 The preserved sponge (03528-1.06 kg, wet weight) was thoroughly dried, ground, and extracted with the accelerated solvent extractor (ASE) first with hexanes, next with CH2Cl2, and last with MeOH under high pressure (1700 psi) at 110 °C (Figure S2).25 The MeOH extract was evaporated in vacuo to produce a brown, viscous oil. This oil was then subjected to preparative reversed-phase (RP) HPLC using a Waters C18, 5 μm particle column to afford five fractions. Fraction 3, which was the major metabolite, was eluted at 60% CH3CN/H2O to yield 5 (9.0 mg). Fraction 1 was also further purified by HPLC to yield 7 (12.2 mg).
Dried sponge samples (collections numbers 05413 and 06123, 1.31 kg wet weight) were extracted using the ASE employing the procedure outlined above (Figure S2). The MeOH-soluble fraction labeled XFM was subjected to preparative RP HPLC using 10-100% CH3CN/H2O to afford six fractions. Fraction 4 contained 5 (5.6 mg) while fraction 3 was further purified by semipreparative RP HPLC at 40% CH3CN/ H2O to yield 6 (1.3 mg).
Leucosolenamine A (5)
9.2 mg, brown solid; 1H NMR (DMSO-d6, 500 MHz) and 13C NMR (DMSO-d6, 125 MHz), see Table 1 and Supporting Information; 1H NMR of 5 was also taken in MeOH-d4, acetone-d6, dioxane-d8, and THF-d6 with and without TFA but no NH’s were observed. NOESY correlations were observed from H-6 (δH 4.05) to H-8 (δH 6.97) and H-12 (δH 6.79) and vice versa; HRFTICRMS [M + H]+ obsd 384.14161 (Δ0.04 mmu vs calc), calcd for C17H18N7O4 384.14165. Hydrogenolysis of 5 was unsuccessful.
Leucosolenamine B (6)
1.3 mg, brown solid; 1H NMR (DMSO-d6, 500 MHz) and 13C NMR (DMSO-d6, 125 MHz), see Table 2 and Supporting Information; ROESY correlations observed were from H-6 (δH 4.01) to H-8 (δH 6.39) and H-12 (δH 6.80) and vice versa; HRESITOFMS [M + H]+ obsd 397.1628 (Δ7.0 mmu vs calc), calcd for C18H21N8O3 397.17311.
Thymidine (7)
12.2 mg, white needles; [α]D +78.0 (c 0.61, H2O); 1H NMR (MeOH-d4, 500 MHz) and 13C NMR (MeOH-d4, 125 MHz), see Supporting Information; HRESITOFMS [M + H]+ obsd 243.10319 (Δ5.6 mmu vs calc), calcd for C10H15N2O5 243.09755.
Supplementary Material
Acknowledgment
Financial support for this research was from NIH grant CA 47135. Prof. Rob van Soest of the University of Amsterdam provided the taxonomic identification of the sponge. Jack Cunniff of Thermo Electron Corporation provided the ultrahigh-resolution FTMS data. We also thank the captain and the crew of the M/V Telita. Special thanks are extended to L. Matainaho of the University of Papua New Guinea for assistance in collection permits.
Footnotes
Supporting Information Available: Compound isolation schemes, underwater and above water photographs of Leucosolenia sp., NMR spectra (1H, 13C NMR, gHMBC, gHMQC, DEPT) and MS spectra of 5, 6, and 7, ACD calculations and MOPAC-minimized structures of 5a and 5b, MS-MS data of 2, 5, and 8. This material is available free of charge via the Internet at http://pubs.acs.org.
References and Notes
- 1.Blunt JW, Copp BR, Munro MHG, Northcote PT, Prinsep MR. Nat. Prod. Rep. 2005;22:15–61. doi: 10.1039/b415080p. [DOI] [PubMed] [Google Scholar]
- 2.a Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH. Mol. Cancer Ther. 2005;4:333–342. [PubMed] [Google Scholar]; b Newman DJ, Cragg GM. J. Nat. Prod. 2004;67:1216–1238. doi: 10.1021/np040031y. [DOI] [PubMed] [Google Scholar]; c Crews P, Gerwick W, Schmitz F, France D, Bair K, Wright A, Hallock Y. Pharm. Biol. 2003;41:39–52. [Google Scholar]
- 3.a Thale Z, Kinder FR, Bair KW, Bontempo J, Czuchta AM, Versace RW, Phillips PE, Sanders ML, Wattanasin S, Crews P. J. Org. Chem. 2001;66:1733–1741. doi: 10.1021/jo001380+. [DOI] [PubMed] [Google Scholar]; b Kinder FR, Jr., Versace RW, Bair KW, Bontempo JM, Cesarz D, Chen S, Crews P, Czuchta AM, Jagoe CT, Mou Y, Nemzek R, Phillips PE, Tran LD, Wang R, Weltchek S, Zabludoff S. J. Med. Chem. 2001;44:3692–3699. doi: 10.1021/jm010188c. [DOI] [PubMed] [Google Scholar]
- 4.a Mooberry SL, Randall-Hlubek DA, Leal RM, Hegde SG, Hubbard RD, Zhang L, Wender PA. Proc. Natl. Acad. Sci. U.S.A. 2004;101:8803–8808. doi: 10.1073/pnas.0402759101. [DOI] [PMC free article] [PubMed] [Google Scholar]; b Quiňoa E, Kakou Y, Crews P. J. Org. Chem. 1988;53:3642–3644. [Google Scholar]
- 5.a Umera D, Takahashi K, Yamamoto T. J. Am. Chem. Soc. 1985;107:4796–4798. [Google Scholar]; b Bai RL, Paul KD, Herald CL, Maspeis L, Pettit GR, Hamel E. J. Biol. Chem. 1991;266:15882–15889. [PubMed] [Google Scholar]; c Dabydeen D, Florence G, Patterson I, Hanel E. Cancer Chemother. Pharmacol. 2004;53:397–403. doi: 10.1007/s00280-003-0755-0. [DOI] [PubMed] [Google Scholar]; d Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA. Cancer Res. 2004;64:5760–5766. doi: 10.1158/0008-5472.CAN-04-1169. [DOI] [PubMed] [Google Scholar]
- 6.a Gunasekera SP, Gunasekera M, Longley RE, Schulte GK. J. Org. Chem. 1990;55:4912–15. [Google Scholar]; b Honore S, Kamath K, Braguer D, Horwitz SB, Wilson L, Briand C, Jordan MA. Cancer Res. 2004;64:4957–4964. doi: 10.1158/0008-5472.CAN-04-0693. [DOI] [PubMed] [Google Scholar]
- 7.Piňa IC, Gautschi JT, Wang G, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB, Bair KW, Crews P. J. Org. Chem. 2003;68:3866–3873. doi: 10.1021/jo034248t. [DOI] [PubMed] [Google Scholar]
- 8.a Crews P, Clark DP, Tenney K. J. Nat. Prod. 2003;66:177–182. doi: 10.1021/np020371o. [DOI] [PubMed] [Google Scholar]; b Ralifo P, Crews P. J. Org. Chem. 2004;69:9025–9029. doi: 10.1021/jo048789+. [DOI] [PubMed] [Google Scholar]; c Edrada RA, Stessman C, Crews P. J. Nat. Prod. 2003;66:939–942. doi: 10.1021/np020503d. [DOI] [PubMed] [Google Scholar]
- 9.a Ciminiello P, Fattorusso E, Magno S, Mangoni A. Tetrahedron. 1989;45:3873–3878. [Google Scholar]; b Ciminiello P, Fattorusso E, Magno S, Mangoni A, Di Blasio B, Pavone V. Tetrahedron. 1990;46:4387–4392. [Google Scholar]; c Hassan W, Edrada R, Ebel R, Wray V, Berg A, Van Soest R, Wiryowidagdo S, Proksch P. J. Nat. Prod. 2004;67:817–822. doi: 10.1021/np0305223. [DOI] [PubMed] [Google Scholar]
- 10.Fu X, Schmitz FJ, Tanner RS, Kelly-Borges MJ. Nat. Prod. 1998;61:384–386. doi: 10.1021/np970453q. [DOI] [PubMed] [Google Scholar]
- 11.Chan GW, Mong S, Hemling ME, Freyer AJ, Offen PH, DeBrosse CW, Sarau HM, Westly JW. J. Nat. Prod. 1993;56:116–121. [PubMed] [Google Scholar]
- 12.Akee RK, Carroll TR, Yoshida WY, Scheuer PJ, Stout T, Clardy JJ. Org. Chem. 1990;55:1944–1946. [Google Scholar]
- 13.Hooper JNA, van Soest RWM. Systema Porifera. A Guide to the Classification of Sponges. Vol. 2. Kluwer Academic/Plenum Publishers; New York: 2002. pp. 1159–1161. [Google Scholar]
- 14.Bioassay procedures are described in: Valeriote F, Grieshaber CK, Media J, Pietraszkewicz H, Hoffmann J, Pan M, McLaughlin S. J. Exp. Ther. Oncol. 2002;2:228–236. doi: 10.1046/j.1359-4117.2002.01038.x.
- 15.a Henry KD, Williams ER, Wang BH, McLafferty FW, Shabanowitz J, Hunt DF. Proc. Natl. Acad. Sci. U.S.A. 1989;86:9075–9078. doi: 10.1073/pnas.86.23.9075. [DOI] [PMC free article] [PubMed] [Google Scholar]; b Zhang LK, Rempel D, Pramanik BN, Gross ML. Mass Spec. Rev. 2005;24:286–309. [Google Scholar]
- 16.Carmely S, Ilan M, Kashman Y. Tetrahedron. 1989;45:2193–2200. [Google Scholar]
- 17.Akee RK, Carroll TR, Yoshida WY, Scheuer PJ, Stout T, Clardy JJ. Org. Chem. 1990;55:1944–1946. [Google Scholar]
- 18.Rychonsky SD. Org. Lett. 2006;8:2895–2898. [Google Scholar]
- 19.a Kozai S, Ogimoto K, Maruyama T. Tetrahedron. 2000;56:1685–769. [Google Scholar]; b Müller CE, Thorand M, Qurishi R, Diekmann M, Jacobson K, Padget WL, Daly J. J. Med. Chem. 2002;45:3440–3450. doi: 10.1021/jm011093d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Segraves NL, Robinson SJ, Garcia D, Said SA, Fu X, Schmitz FJ, Pietraszkiewicz H, Valeriote FA, Crews PJ. Nat. Prod. 2004;67:783–792. doi: 10.1021/np049935+. [DOI] [PubMed] [Google Scholar]
- 21.Sadique J, Shanmugasundaram R, Shanmugasundaram ER. Naturwissenschaften. 1966;53:282–286. doi: 10.1007/BF00621663. [DOI] [PubMed] [Google Scholar]
- 22.Capon RJ, Skene C, Vuong D, Lacey E, Gill JH, Heiland K, Friedel TJ. Nat. Prod. 2002;65:368–370. doi: 10.1021/np010337u. [DOI] [PubMed] [Google Scholar]
- 23.Cardellina JH, Menwald JJ. Org. Chem. 1981;46:4782–4784. [Google Scholar]
- 24.Jaspars M, Rali T, Laney M, Schatzman RC, Diaz MC, Schmitzs FJ, Pordesimo EO, Crews P. Tetrahedron. 1994;50:7367–7373. [Google Scholar]
- 25.A side-by-side comparison of sponge samples extracted using the ASE and successive soaking in solvent produced crude oils containing identical chemical profiles by LCMS. In addition, we have isolated the bengamides and the jasplakinolides using the ASE. Advantages of using the ASE include higher yields and low consumption of solvents.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.





